NASDAQ: ABVC - ABVC BioPharma, Inc.

半年間の収益性: -3.24%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール ABVC BioPharma, Inc.


会社について ABVC BioPharma, Inc.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

さらに詳しく
The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

IPO date 2017-10-11
ISIN US00091F1066
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.abvcpharma.com
Цена ао 0.688
1日あたりの価格変動: +0.0155% (0.6459)
週ごとの価格変動: +2.15% (0.6324)
月ごとの料金変更: +54.18% (0.419)
3ヶ月間の価格変動: +26.67% (0.51)
半年間の価格変動: -3.24% (0.6676)
年間の価格変動: -44.31% (1.16)
3年間の価格推移: -71.67% (2.28)
5年間の価格推移: -89.58% (6.2)
10年間の価格推移: +0% (0.646)
年初からの価格変動: +9.36% (0.5907)

過小評価

名前 意味 学年
P/S 34.42 1
P/BV 0.6113 10
P/E 0 0
EV/EBITDA -0.8525 0
合計: 4.25

効率

名前 意味 学年
ROA, % -70.37 0
ROE, % -118.96 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.2994 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % -78.29 0
収益性 Ebitda, % 146.44 10
収益性 EPS, % 7.8 1
合計: 5.2



スーパーバイザー 役職 支払い 生年
Mr. Eugene Jiang Chairman & Chief Business Officer 200k 1986 (39 年)
Dr. Tsung-Shann Jiang EMBA, Ph.D. Chief Scientific Officer, Chief Strategy Officer & Director 200k 1954 (71 年)
Dr. Uttam Yashwant Patil Ph.D. CEO & Interim CFO N/A 1986 (39 年)

住所: United States, Fremont. CA, 44370 Old Warm Springs Boulevard - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.abvcpharma.com